ALTO Alto Ingredients, Inc.
Industrial Organic Chemicals · Nasdaq · SEC CIK 778164 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY4.1%
TTM net income YoY201.2%
TTM EPS YoY192.9%
Revenue 3-yr CAGR-9.1%
Net income 3-yr CAGR—
Margins
Gross margin5.8%
Operating margin2.7%
Net margin5.3%
FCF margin3.9%
EBITDA margin5.4%
Returns
ROE20.5%
ROA12.8%
ROIC (approx.)8.6%
Asset turnover2.43x
Leverage & solvency
Liabilities / assets32.1%
Debt / equity0.20x
Current ratio3.39x
Interest coverage3.16x
Cash quality & payout
Operating cash flow / net income1.08x
Accruals ratio-1.1%
Payout ratio—
Capex / revenue1.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $917.93M | $965.26M |
| Cost of revenue | $883.01M | $955.54M |
| Gross profit | $34.91M | $9.72M |
| SG&A expense | $27.21M | $29.74M |
| Operating income | $7.36M | -$51.67M |
| Interest expense | $10.77M | $7.64M |
| Pretax income | $12.72M | -$58.81M |
| Income tax | -$621,000 | $173,000 |
| Net income | $13.34M | -$58.98M |
| EBITDA | $32.58M | -$27.27M |
| EPS (basic) | 0.16 | -0.82 |
| EPS (diluted) | 0.16 | -0.82 |
| Weighted avg. shares (diluted) | 75.66M | 73.48M |
| Balance sheet | ||
| Cash & equivalents | $23.41M | $36.21M |
| Receivables | $55.07M | $58.22M |
| Inventory | $61.68M | $49.91M |
| Current assets | $155.92M | $153.12M |
| PP&E, net | $198.50M | $214.74M |
| Intangibles | $7.57M | $4.51M |
| Total assets | $388.79M | $401.44M |
| Current liabilities | $59.07M | $57.80M |
| Short-term debt | $16.60M | — |
| Long-term debt | $63.03M | $92.90M |
| Total debt | $79.63M | $92.90M |
| Total liabilities | $143.54M | $176.38M |
| Shareholders' equity | $245.24M | $225.06M |
| Net debt | $56.21M | $56.69M |
| Shares outstanding | 77.31M | 76.57M |
| Cash flow statement | ||
| Operating cash flow | $13.24M | -$3.52M |
| Capital expenditure | $4.60M | $11.07M |
| Free cash flow | $8.65M | -$14.59M |
| Investing cash flow | -$7.43M | -$13.47M |
| Financing cash flow | -$16.36M | $7.72M |
| Depreciation & amortization | $25.22M | $24.41M |
| Stock-based compensation | $3.02M | $4.36M |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.